Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Regulation of cell signalling by uPAR.

Smith HW, Marshall CJ.

Nat Rev Mol Cell Biol. 2010 Jan;11(1):23-36. doi: 10.1038/nrm2821. Review.

PMID:
20027185
2.

Role of urokinase receptor in tumor progression and development.

Noh H, Hong S, Huang S.

Theranostics. 2013 Jun 25;3(7):487-95. doi: 10.7150/thno.4218. Print 2013. Review.

3.

RhoB regulates uPAR signalling.

Alfano D, Ragno P, Stoppelli MP, Ridley AJ.

J Cell Sci. 2012 May 15;125(Pt 10):2369-80. doi: 10.1242/jcs.091579. Epub 2012 Feb 24.

4.

The urokinase receptor as an entertainer of signal transduction.

D'Alessio S, Blasi F.

Front Biosci (Landmark Ed). 2009 Jan 1;14:4575-87. Review.

PMID:
19273372
5.

The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling.

Carriero MV, Stoppelli MP.

Curr Pharm Des. 2011;17(19):1944-61. Review.

PMID:
21711235
6.

Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism.

Czekay RP, Loskutoff DJ.

J Cell Physiol. 2009 Sep;220(3):655-63. doi: 10.1002/jcp.21806.

7.

The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.

Hildenbrand R, Schaaf A.

Int J Oncol. 2009 Jan;34(1):15-23.

PMID:
19082473
8.
9.

The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling.

Blasi F, Sidenius N.

FEBS Lett. 2010 May 3;584(9):1923-30. doi: 10.1016/j.febslet.2009.12.039. Epub 2009 Dec 27. Review.

10.

Discovery of new small molecules targeting the vitronectin-binding site of the urokinase receptor that block cancer cell invasion.

Rea VE, Lavecchia A, Di Giovanni C, Rossi FW, Gorrasi A, Pesapane A, de Paulis A, Ragno P, Montuori N.

Mol Cancer Ther. 2013 Aug;12(8):1402-16. doi: 10.1158/1535-7163.MCT-12-1249. Epub 2013 May 22.

11.

Regulation and role of urokinase plasminogen activator in vascular remodelling.

Tkachuk V, Stepanova V, Little PJ, Bobik A.

Clin Exp Pharmacol Physiol. 1996 Sep;23(9):759-65. Review.

PMID:
8911711
13.

uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors.

Montuori N, Cosimato V, Rinaldi L, Rea VE, Alfano D, Ragno P.

Thromb Haemost. 2013 Feb;109(2):309-18. doi: 10.1160/TH12-08-0546. Epub 2012 Dec 13.

PMID:
23238745
14.

The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.

Sidenius N, Blasi F.

Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):205-22. Review.

PMID:
12784997
15.

The interaction between urokinase receptor and vitronectin in cell adhesion and signalling.

Madsen CD, Sidenius N.

Eur J Cell Biol. 2008 Sep;87(8-9):617-29. doi: 10.1016/j.ejcb.2008.02.003. Epub 2008 Mar 18. Review.

PMID:
18353489
16.
18.

TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression.

Sugioka K, Kodama A, Okada K, Iwata M, Yoshida K, Kusaka S, Matsumoto C, Kaji H, Shimomura Y.

Exp Eye Res. 2013 Oct;115:13-21. doi: 10.1016/j.exer.2013.06.020. Epub 2013 Jun 28.

PMID:
23810810
19.

uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy.

Lund IK, Illemann M, Thurison T, Christensen IJ, Høyer-Hansen G.

Curr Drug Targets. 2011 Nov;12(12):1744-60. Review.

PMID:
21707477
20.

Differential proteome expression associated with urokinase plasminogen activator receptor (uPAR) suppression in malignant epithelial cancer.

Saldanha RG, Xu N, Molloy MP, Veal DA, Baker MS.

J Proteome Res. 2008 Nov;7(11):4792-806. doi: 10.1021/pr800357h. Epub 2008 Sep 23.

PMID:
18808175
Items per page

Supplemental Content

Write to the Help Desk